FeesSafety
Pluang+
Home/Explore/US Market Price/Stocks/AMGN
icon
Up to 4x
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Amgen, Inc. (AMGN) Stock Price Today

TechnicalsFundamentalsFinancialsNewsCorp ActionAboutCompare
24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

Amgen (AMGN) trades at $460.73, up 2.85% with strong technical momentum as price approaches resistance at $463. The stock shows robust fundamentals with three consecutive earnings beats, 22.95% net margin, and positive Phase 3 results for dazodalibep in Sjögren's disease. Revenue growth accelerated to $36.75B in 2025, though high debt levels and acquisition costs present challenges.
Outlook remains positive with analyst consensus at Buy (54%) and $403.79 price target, though current price exceeds consensus. Key opportunities include pipeline expansion in autoimmune diseases, while risks center on debt servicing and competitive pressures in biotech. The stock trades near 52-week highs with bullish technical indicators supporting further upside potential.
Read full analysis

Key Stats

  • Market Cap
    $244.27B
  • Volume
    2,812,745
  • Sector
    Health
  • 52W High
    $451.83
  • 52W Low
    $291.77
  • Typical Hold Time
    73 Days
  • Enterprise Value
    $287.59B
  • Div Yield
    2.23%
  • Trading Activity
    46% Sell | 54% Buy
$470.86
52W Low: $291.77
29 Oct 2025
52W High: $470.86
30 Oct 2026

Track Amgen, Inc. (AMGN) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Amgen, Inc. has traded between a low of $291.77 and a high of $470.86, highlighting its annual price range. Buy and sell Amgen, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Most Recent News

Content is generated by Aura AI

FirstCash shares drop 14.75% after Q3 income and loan volume fall, sparking securities fraud probe.

FirstCash Holdings, Inc. shares fell 14.75% on October 22, 2026, after the company reported a 28% year-over-year decline in operating income for its American First Finance segment and a 15% drop in lease and loan originations for Q3. The decline was ...

Market News
1 hour ago
The Law Offices Of Frank R. Cruz
Bearish
news icon
FirstCash shares drop 14.75% after Q3 income and loan volume fall, sparking securities fraud probe.

Westmark Enterprises data breach exposes personal info; law firm investigates class action claims.

Westmark Enterprises experienced a data breach in August 2026, where unauthorized access to its network potentially exposed personal information such as names and Social Security numbers. The company began notifying affected individuals in October an...

Market News
3 hours ago
Edelson Lechtzin Llp
Bearish
news icon
Westmark Enterprises data breach exposes personal info; law firm investigates class action claims.

AI models doubt Hyperliquid (HYPE) will hit $150 by end of 2026 despite recent surge and Wall Street interest.

Hyperliquid (HYPE) surged 18.3% to $95 but AI models ChatGPT and Grok predict it is unlikely to reach $150 by the end of 2026. The price target depends heavily on regulatory approval for a U.S. market of Hyperliquid perpetual futures, backed by Inter...

Market News
4 hours ago
24/7 Wall Street
Neutral
AI models doubt Hyperliquid (HYPE) will hit $150 by end of 2026 despite recent surge and Wall Street interest.
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

People also bought

Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.
US Stocks, ETFs, and Options are facilitated by PT PG Berjangka in its capacity as a Licensed Derivatives Broker supervised by the Financial Services Authority of Indonesia (OJK) for financial derivative products with underlying securities. All transactions are recorded on the Jakarta Futures Exchange (JFX) and the Indonesian Futures Clearing House (KBI). In addition, PT PG Berjangka is also a Licensed Futures Broker supervised by the Commodity Futures Trading Regulatory Agency (Bappebti). Read our product’s Terms and Conditions

All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.

Key Stats

  • Market Cap
    $244.27B
  • Volume
    2,812,745
  • Sector
    Health
  • 52W High
    $451.83
  • 52W Low
    $291.77
  • Typical Hold Time
    73 Days
  • Enterprise Value
    $287.59B
  • Div Yield
    2.23%
  • Trading Activity
    46% Sell | 54% Buy
$470.86
52W Low: $291.77
29 Oct 2025
52W High: $470.86
30 Oct 2026

Track Amgen, Inc. (AMGN) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Amgen, Inc. has traded between a low of $291.77 and a high of $470.86, highlighting its annual price range. Buy and sell Amgen, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!